Viridian Therapeutics (UK) Insiders

Viridian Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.3032) % which means that it has lost $0.3032 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4848) %, meaning that it generated substantial loss on money invested by shareholders. Viridian Therapeutics' management efficiency ratios could be used to measure how well Viridian Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Viridian Therapeutics' Total Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 992.8 K in 2025, whereas Non Current Assets Total are likely to drop slightly above 2.7 M in 2025. Common Stock Shares Outstanding is likely to gain to about 71.3 M in 2025, despite the fact that Net Loss is likely to grow to (111 M).

Viridian Therapeutics Workforce Comparison

Viridian Therapeutics Benchmark Summation

Viridian Therapeutics Notable Stakeholders

The success or failure of an entity such as Viridian Therapeutics often depends on how effective the management is. Viridian Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Viridian management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Viridian management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Viridian Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Viridian Therapeutics. Check Viridian Therapeutics' Beneish M Score to see the likelihood of Viridian Therapeutics' management manipulating its earnings.

When running Viridian Therapeutics' price analysis, check to measure Viridian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viridian Therapeutics is operating at the current time. Most of Viridian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viridian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viridian Therapeutics' price. Additionally, you may evaluate how the addition of Viridian Therapeutics to your portfolios can decrease your overall portfolio volatility.